Skip to main content

Anticoagulants Market Size [2019-2026] worth USD 45.50 Billion | Exhibit a CAGR of 9.9%

Anticoagulants Market to Reach USD 45.50 Billion by 2026; Increased Awareness and Innovation of Blood Thinners to Drive Market Growth: Fortune Business Insights™

Pune, India, March 07, 2022 (GLOBE NEWSWIRE) — The global anticoagulants market size is projected to reach 45.50 billion by the end of 2026. According to a report published by Fortune Business Insights, titled “Anticoagulants Market Size, Share & Industry Analysis, By Disease Indication (Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Atrial Fibrillation, Heart Attacks, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026,” the market was worth USD 21.45 billion in 2018 and will exhibit a CAGR of 9.9% during the forecast period,2019-2026.

Anticoagulants are widely used across the healthcare industry for the treatment of several cardiovascular and health-related disorders. They are effectively used to treat blood clots avoid blockage of blood flow that is caused due to these drugs. The demand for anticoagulants has risen dramatically in recent years, owing to its exceptional properties. Anticoagulants are included in major drugs that are prescribed for the treatment of cardiovascular diseases. The properties of anticoagulants have led to a high product adoption in diverse industries. The increasing emphasis on the severe effects of unattended cardiovascular diseases will fuel the demand for anticoagulants.

Request a Sample Copy of Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/anticoagulants-market-101807

Key Industry Developments:

February 2019: Novartis AG and Blackstone’s Life Sciences announced the launch of Anthos Therapeutics, a product aimed at the development of new and pipeline drugs that are comprised of anticoagulants.

October 2019: Janssen Pharmaceuticals received approval from the US Food and Drug Administration for usage of Riveraxoban, a drug aimed at the treatment of thromboembolic complications.

Report Scope & Segmentation

Report CoverageDetails
Forecast Period2019 to 2026
Forecast Period 2021 to 2026 CAGR9.9%
2026 Value ProjectionUSD 45.50 Billion
Base Year2018
Market Size in 2026USD 21.45 Billion
Historical Data for2015 to 2017
No. of Pages149
Segments coveredBy Disease Indication, By Route of Administration, end-Users and Geography
Growth DriversIncreased Awareness and Innovation of Blood Thinners is likely to propel the Global Market
Increasing Need for Advanced and Effective Drugs to Drive the Global Market
Pulmonary Embolism (PE) Segment is Likely to Generate the Highest Growth Rate


To get to know more about the short-term and long-term impact of COVID-19 on this market, Please Visit: https://www.fortunebusinessinsights.com/industry-reports/anticoagulants-market-101807


The report offers insights into the latest anticoagulants market trends. It highlights leading companies in the market and discusses the strategies that these companies have adopted in recent years. The competitive landscape scenario has been discussed in detail. Additionally, the report encompasses several factors that have contributed to the growth of the market in recent years. Forecast values of the market have been provided for the period of 2019-2026. The market has been segmented on the basis of several criteria including route of administration, distribution type, and disease indication. Factual figures have been evaluated through trusted sources. Other forecast valued have been gathered through interviews and opinions of experienced market research professionals.

Increasing Number of Company Mergers Will Aid Market Growth

Several growth stimulating factors have been analyzed and discussed in detail. Among all factors, the increasing number of company mergers have had the highest impact on the market. In February 2019, Novartis AG and Blackstone’s LifeSciences announced the launch of Anthos Therapeutics. The company is aiming for the research and development of drugs that include anticoagulants as a prime pipeline candidate. Increasing number of drug approvals is another factor that has constituted an increase in the global anticoagulants market size in recent years. Janssen Pharmaceuticals’ Rivaroxaban is an example of a recent drug approval that has had a direct impact on the market.

Quick Buy – Anticoagulants Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101807

North America to Emerge Dominant; High Prevalence of Cardiovascular Disease to Create Several Growth Opportunities

The market is segmented on the basis of regional demographics into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among these regions, North America will emerge dominant in the coming years. The high prevalence of cardiovascular disease, coupled with the increasing emphasis on the research and development of new drugs will open up a huge potential for the companies operating in the market in this market. As of 2018, the market in North America was worth USD 10.10 billion. Besides North America, Europe will witness significant growth in the coming years, owing to the high incidence of deaths caused due to cardiovascular disease in several countries across this region. The high demand for anticoagulants in emerging countries such as Germany, France, and UK will have a positive influence on the growth of the market in this region.

Some of the leading companies that are operating in the global market are:

  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Bayer AG
  • Janssen Pharmaceuticals, Inc.
  • Eisai Co., Ltd.
  • Other Prominent Players

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/anticoagulants-market-101807

Table of Content from Anticoagulants Market:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Prevalence of Major Cardiovascular Diseases by Key Countries
    • Overview of Novel Oral Anticoagulants (NOACs)
    • Pipeline Analysis
    • Key Industry Developments Such as Mergers & Acquisitions
    • New Product Launches
    • Regulatory Scenario in Key Countries
    • Reimbursement Scenario by Key Countries
  • Global Anticoagulants Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Disease Indication
      • Pulmonary Embolism (PE)
      • Deep Vein Thrombosis (DVT)
      • Atrial Fibrillation
      • Heart Attacks
      • Others
    • Market Analysis, Insights and Forecast – By Route of Administration
      • Oral
      • Injectable
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospitals Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • Others
    • Market Analysis, Insights and Forecast – By Country
      • North America
      • Europe
      • Asia pacific
      • Latin America
      • Middle East & Africa

TOC Continued….

Ask for Customization of this Report: https://www.fortunebusinessinsights.com/enquiry/customization/anticoagulants-market-101807

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.